Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.
about
HIV-associated neurocognitive disorder--pathogenesis and prospects for treatmentRole of MRP transporters in regulating antimicrobial drug inefficacy and oxidative stress-induced pathogenesis during HIV-1 and TB infectionsAnti-HIV-1 nanotherapeutics: promises and challenges for the futureStudies of retroviral infection in humanized miceNew generation humanized mice for virus research: comparative aspects and future prospectsThe potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trialsCombinatorial assessments of brain tissue metabolomics and histopathology in rodent models of human immunodeficiency virus infectionCellular Responses and Tissue Depots for Nanoformulated Antiretroviral TherapyPharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations.Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance.Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapiesPharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants.Associations between brain microstructures, metabolites, and cognitive deficits during chronic HIV-1 infection of humanized miceThe clinical role and cost-effectiveness of long-acting antiretroviral therapyHumanized mouse models for HIV-1 infection of the CNS.Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized miceInfluence of age, irradiation and humanization on NSG mouse phenotypes.Manganese-Enhanced Magnetic Resonance Imaging Reflects Brain Pathology During Progressive HIV-1 Infection of Humanized Mice.Migration of CD8+ T Cells into the Central Nervous System Gives Rise to Highly Potent Anti-HIV CD4dimCD8bright T Cells in a Wnt Signaling-Dependent MannerThe mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapyImprovements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary.Characterization of neuropathology in the HIV-1 transgenic rat at different ages.HIV-1 cellular and tissue replication patterns in infected humanized mice.Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacityPreclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapyMacrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infectionsHIV-specific CD8⁺ T-cell immunity in humanized bone marrow-liver-thymus miceHuman hepatocytes and hematolymphoid dual reconstitution in treosulfan-conditioned uPA-NOG mice.An Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection.A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapyNanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous systemLong-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients.Multispectral imaging: a review of its technical aspects and applications in anatomic pathology.New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents.Macrophages associated with tumors as potential targets and therapeutic intermediates.Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND)Latest animal models for anti-HIV drug discovery.Development of europium doped core-shell silica cobalt ferrite functionalized nanoparticles for magnetic resonance imaging.Brain Invasion by CD4(+) T Cells Infected with a Transmitted/Founder HIV-1BJZS7 During Acute Stage in Humanized Mice.
P2860
Q26766448-D87A8F77-38A5-41B7-997C-9F5CC4B561DCQ26781386-7322DCA7-97F8-41E8-ADA8-909734D211F2Q26828464-8C460E74-CB22-4906-AF74-5CCEE4293947Q26849806-C3D3B5E3-F25E-442C-BAAC-AFEEC55CA2A1Q27014786-F0818D11-1F78-4C6B-AE3B-54B0907F1F60Q28087336-174952E4-0DD2-4987-8F73-863469451CC4Q28394163-F6308A30-505A-4242-84BF-9182906EECE8Q28551873-04222365-4682-42CD-9552-83C2BA05215BQ30603781-33CE2488-1B46-4A5E-8D18-D4AC570D344FQ34059457-8C84AAED-B8AE-43AB-A500-82EE0D183B2EQ34745586-3967E4CD-306B-42C6-B3CB-74007EC9CD13Q34797004-5C66FD19-0B99-44AF-81A0-731B82AF9854Q34922985-207F82F7-3AB9-41C2-9E3C-5915140F8366Q34979163-B6C9FBB1-D93E-49A8-826D-5AEA007EB945Q35197271-6B2877A5-64E3-4F7C-A3D4-D622A51C7370Q35567215-701BCE25-F4A6-4641-B77A-557A795684A4Q35822619-14D1520E-BD67-4FF0-B419-ECBA70AC2F3BQ36175327-ECC9A560-9C31-4ACF-A6BB-59CDC97BDD41Q36365764-7FB8E6F0-ED68-4A9F-9F72-2E912FC52E2CQ36387228-17C557A7-B299-4365-A1B0-75191D539671Q36505647-4D9BE186-580F-4B85-AC1C-2FBAB3EA976CQ36601983-08E5972B-B07D-4DD0-B86E-FF532ACC19CCQ36655192-BA9C271C-4E45-43A5-B80C-0DFCDAF2F2F9Q36709101-1582E519-4193-456C-937C-F917E21C65F7Q36875347-6F752995-2132-456E-8BD8-3C1B8A4B9F37Q36969787-99CC9EB5-E9D0-465C-9DCB-925F29842F08Q37188867-1ADDBC1F-1154-413C-8BA9-3D9B7858C744Q37254475-60F99C27-6C70-4871-B77C-24BEA631073EQ37415420-CDDF3A7B-CC54-4B14-B488-CE21697C2112Q37538618-15D0D1C4-6522-4E3F-A7C0-9BC69EB46675Q37692595-00895A41-B976-434F-BF07-F5B6C4D29BEBQ37698620-25A402FB-13F2-4376-AABA-3163EF6A3286Q37704651-0D1D3040-505B-4F09-BDAF-5D787D7989CBQ38152999-9BD3168B-ED8B-43FE-8D09-A06D04A51590Q38170326-4CBBD0D9-4B4B-45B9-B192-687D3BE04790Q38211726-3764539E-EE54-4D40-806E-55070F3C3310Q38217388-CAB95958-B83F-477B-8A70-320DD4DCB6D0Q38263295-9884D1C5-A63E-475E-A822-5EBD55F13B48Q38787356-CF4F3FD5-5E7B-4355-9A58-BCA299A83859Q38912920-92889899-AAFC-47C1-9933-E35FD0893E3B
P2860
Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Long-acting nanoformulated ant ...... HIV-1-infected humanized mice.
@ast
Long-acting nanoformulated ant ...... HIV-1-infected humanized mice.
@en
type
label
Long-acting nanoformulated ant ...... HIV-1-infected humanized mice.
@ast
Long-acting nanoformulated ant ...... HIV-1-infected humanized mice.
@en
prefLabel
Long-acting nanoformulated ant ...... HIV-1-infected humanized mice.
@ast
Long-acting nanoformulated ant ...... HIV-1-infected humanized mice.
@en
P2093
P2860
P50
P1433
P1476
Long-acting nanoformulated ant ...... HIV-1-infected humanized mice
@en
P2093
Howard E Gendelman
Joellyn McMillan
Prasanta K Dash
Rodney L Mosley
Santhi Gorantla
Shantanu Balkundi
Yazen Alnouti
P2860
P304
P356
10.1097/QAD.0B013E328357F5AD
P407
P577
2012-11-01T00:00:00Z